Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy.

Kim WT, Kim J, Yan C, Jeong P, Choi SY, Lee OJ, Chae YB, Yun SJ, Lee SC, Kim WJ.

Ann Oncol. 2014 May;25(5):974-9. doi: 10.1093/annonc/mdu037. Epub 2014 Mar 14.

PMID:
24631944
[PubMed - in process]
2.

A four-gene signature predicts disease progression in muscle invasive bladder cancer.

Kim WJ, Kim SK, Jeong P, Yun SJ, Cho IC, Kim IY, Moon SK, Um HD, Choi YH.

Mol Med. 2011 May-Jun;17(5-6):478-85. doi: 10.2119/molmed.2010.00274. Epub 2011 Feb 4.

PMID:
21308147
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.

Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R; Head and Neck Cancer Disease Site Group.

Curr Oncol. 2010 Jun;17(3):37-48.

PMID:
20567625
[PubMed]
Free PMC Article
4.

FAM70B as a Novel Prognostic Marker for Cancer Progression and Cancer-Specific Death in Muscle-Invasive Bladder Cancer.

Kang HW, Yoon HY, Ha YS, Kim WT, Kim YJ, Yun SJ, Lee SC, Kim WJ.

Korean J Urol. 2012 Sep;53(9):598-606. doi: 10.4111/kju.2012.53.9.598. Epub 2012 Sep 19.

PMID:
23060996
[PubMed]
Free PMC Article
6.

Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.

Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, Pollack A, Sandler H, Shipley W.

Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):309-17.

PMID:
15890569
[PubMed - indexed for MEDLINE]
7.

Gene expression and prognosis in bladder cancer--real progress? Editorial on 'S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy'.

Symanowski JT, Kim ES.

Ann Oncol. 2014 May;25(5):919-20. doi: 10.1093/annonc/mdu113. Epub 2014 Mar 7. No abstract available.

PMID:
24608197
[PubMed - in process]
8.

Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer.

Shim UJ, Lee IS, Kang HW, Kim J, Kim WT, Kim IY, Ryu KH, Choi YH, Moon SK, Kim YJ, Yun SJ, Lee SC, Kim WJ.

Korean J Urol. 2013 Sep;54(9):631-7. doi: 10.4111/kju.2013.54.9.631. Epub 2013 Sep 10.

PMID:
24044099
[PubMed]
Free PMC Article
9.

Epidermal growth factor receptor status predicts local response to radical radiotherapy in muscle-invasive bladder cancer.

Colquhoun AJ, Sundar S, Rajjayabun PH, Griffiths TR, Symonds RP, Mellon JK.

Clin Oncol (R Coll Radiol). 2006 Nov;18(9):702-9.

PMID:
17100158
[PubMed - indexed for MEDLINE]
10.

Novel combination markers for predicting survival in patients with muscle invasive bladder cancer: USP18 and DGCR2.

Kim YH, Kim WT, Jeong P, Ha YS, Kang HW, Yun SJ, Moon SK, Choi YH, Kim IY, Kim WJ.

J Korean Med Sci. 2014 Mar;29(3):351-6. doi: 10.3346/jkms.2014.29.3.351. Epub 2014 Feb 27.

PMID:
24616583
[PubMed - in process]
Free PMC Article
11.

Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer.

Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, Lee SC, Cha EJ, Bae SC.

Mol Cancer. 2010 Jan 8;9:3. doi: 10.1186/1476-4598-9-3.

PMID:
20059769
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Glutathione S-transferase M1 and T1 polymorphisms: susceptibility and outcomes in muscle invasive bladder cancer patients.

Kang HW, Song PH, Ha YS, Kim WT, Kim YJ, Yun SJ, Lee SC, Choi YH, Moon SK, Kim WJ.

Eur J Cancer. 2013 Sep;49(14):3010-9. doi: 10.1016/j.ejca.2013.05.019. Epub 2013 Jun 26.

PMID:
23810248
[PubMed - indexed for MEDLINE]
13.

Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer.

Nordentoft I, Dyrskjøt L, Bødker JS, Wild PJ, Hartmann A, Bertz S, Lehmann J, Orntoft TF, Birkenkamp-Demtroder K.

BMC Cancer. 2011 Apr 14;11:135. doi: 10.1186/1471-2407-11-135.

PMID:
21489314
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.

Wallerand H, Cai Y, Wainberg ZA, Garraway I, Lascombe I, Nicolle G, Thiery JP, Bittard H, Radvanyi F, Reiter RR.

Urol Oncol. 2010 Mar-Apr;28(2):180-8. doi: 10.1016/j.urolonc.2008.09.041. Epub 2008 Dec 12.

PMID:
19070520
[PubMed - indexed for MEDLINE]
15.

Three-gene signature predicts disease progression of non-muscle invasive bladder cancer.

Jeong P, Ha YS, Cho IC, Yun SJ, Yoo ES, Kim IY, Choi YH, Moon SK, Kim WJ.

Oncol Lett. 2011 Jul;2(4):679-684. Epub 2011 May 13.

PMID:
22848249
[PubMed]
Free PMC Article
16.

KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2010;10(25):1-49. Epub 2010 Dec 1.

PMID:
23074403
[PubMed]
Free PMC Article
17.

Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.

Kim JS, Chae Y, Ha YS, Kim IY, Byun SS, Yun SJ, Kim WJ.

Clin Genitourin Cancer. 2012 Jun;10(2):114-20. doi: 10.1016/j.clgc.2011.12.003. Epub 2012 Feb 28.

PMID:
22382007
[PubMed - indexed for MEDLINE]
18.

Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.

Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F.

Clin Cancer Res. 2002 Nov;8(11):3438-44.

PMID:
12429632
[PubMed - indexed for MEDLINE]
Free Article
19.

Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer.

Als AB, Dyrskjøt L, von der Maase H, Koed K, Mansilla F, Toldbod HE, Jensen JL, Ulhøi BP, Sengeløv L, Jensen KM, Orntoft TF.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4407-14.

PMID:
17671123
[PubMed - indexed for MEDLINE]
Free Article
20.

Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy.

Chua DT, Nicholls JM, Sham JS, Au GK.

Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):11-20.

PMID:
15093894
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk